A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

DTaP5-HBV-IPV-Hib (Vaxelis®) is a hexavalent combination vaccine (HV) indicated in infants and toddlers for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Switching between HVs during the childhood vaccination...

全面介绍

书目详细资料

发表在:	Human Vaccines & Immunotherapeutics
Main Authors:	Andrea Guerra, Claudio Costantino, Federico Martinon-Torres, Soeren Westerholt, Courtney Lambeth, Ziqiang Chen, Jessie Lumley, Tomas Marcek, David Johnson, Marissa Wilck
格式:	文件
语言:	英语
出版:	Taylor & Francis Group 2024-12-01
主题:	Vaxelis hexavalent combination vaccine interchangeability vaccine safety immunogenicity
在线阅读:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2310900